Form 4: Ocular Therapeutix CDO Sells Shares for Tax Obligations
Insider Transaction Report
Ocular Therapeutix's Chief Development Officer, Peter Kaiser, sold 3,011 shares of common stock at a weighted average price of $12.04 to cover tax withholding obligations related to restricted stock unit vesting.
Summary
- Peter Kaiser, Chief Development Officer of Ocular Therapeutix, Inc., disposed of 3,011 shares of common stock.
- The shares were sold on August 25, 2025, at a weighted average price of $12.04 per share, with individual sales ranging from $11.89 to $12.1548.
- The sale was executed under a pre-arranged Rule 10b5-1 plan, adopted on April 9, 2024.
- The purpose of the sale was to satisfy tax withholding obligations associated with the vesting of restricted stock units on August 22, 2025.
- This transaction was explicitly stated as not being a discretionary trade by the reporting person.
- Following the transaction, Peter Kaiser beneficially owns 204,093 shares of Ocular Therapeutix common stock.
Sentiment
Score: 5
Explanation: The transaction is neutral. It's a non-discretionary sale for tax purposes, which is a routine event for executives with equity compensation and does not reflect a change in confidence in the company.
Positives
- The sale was non-discretionary, executed under a pre-arranged Rule 10b5-1 plan, indicating planned financial management rather than a sudden loss of confidence in the company.
Negatives
- A reduction in direct beneficial ownership by a key executive, even if for tax purposes, slightly decreases management's direct equity stake in the company.
Risks
- No specific risks related to the company's operations or financial health are mentioned. The primary 'risk' is the potential misinterpretation of the sale as a discretionary action rather than a routine tax-related event.
Future Outlook
NA
Management Comments
- The sales do not represent a discretionary trade by the reporting person.
Industry Context
This is an insider transaction filing (Form 4) and does not provide information relevant to broader industry trends or competitive analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Delegation of Authority | Peter Kaiser granted a Power of Attorney to several individuals (Donald Notman, Todd Anderman, Jason Robins, Philip Koesters, Kathleen Theriault) to prepare, execute, submit, and file SEC forms (including Forms 3, 4, 5, Schedules 13D/G, and Forms 144) on his behalf, and to manage his EDGAR account. | 2025-06-11 | Enhances efficiency and ensures timely compliance with SEC reporting requirements for the reporting person, reducing administrative burden while maintaining accountability. |
Stakeholder Impact
- Shareholders: The sale slightly reduces the direct beneficial ownership of a key executive. However, as a non-discretionary tax-related transaction, it is unlikely to signal a change in management's long-term view or have a significant negative impact on shareholder confidence.
Next Steps
- The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request to Ocular Therapeutix, Inc. or the staff of the Securities and Exchange Commission.
Key Dates
| Date | Description |
|---|---|
| 2024-04-09 | Date Peter Kaiser adopted the durable automatic sale instruction (Rule 10b5-1 plan). |
| 2025-06-11 | Date Peter Kaiser executed the Power of Attorney. |
| 2025-08-22 | Date of vesting of restricted stock units. |
| 2025-08-25 | Date of transaction (sale of common stock). |
| 2025-08-27 | Date the Form 4 was signed. |
Recommendation
holdThe transaction is a routine, non-discretionary sale by an executive to cover tax obligations associated with restricted stock unit vesting. It does not indicate a change in the executive's confidence in the company or provide new information that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate based solely on this filing.
Keywords
Ocular Therapeutix, OCUL, Peter Kaiser, Chief Development Officer, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.